Myelo Therapeutics

Myelo Therapeutics is a clinical-stage biotech company advancing Myelo001, a small molecule with dual applications in biodefense and oncology supportive care. The company's mission is to address the severe health consequences of radiation exposure, whether from a nuclear incident or cancer therapy, by developing treatments to mitigate bone marrow toxicity. Its programs are supported by prestigious grants from the US National Institutes of Health and the European Commission's European Defence Fund. Following its 2023 acquisition by isotope technology leader Eckert & Ziegler, Myelo operates as a strategically positioned subsidiary with enhanced resources for development.

Small molecule (Myelo001) platform targeting hematopoiesis, with a dual mechanism of cytoprotection for immature myeloid cells and induction of neutrophil differentiation. Administered orally.

In biodefense, competitors include other companies developing radiation MCMs (e.g., neutrophil stimulants, cytokines, cell therapies) for government contracts. In supportive care, Myelo001 would compete directly with established injectable G-CSFs like filgrastim and pegfilgrastim (Neulasta), their biosimilars, and other emerging oral therapies targeting myelosuppression.